A Phase 1b Study of PEGylated Recombinant Human Hyaluronidase (PEGPH20) Combined With Docetaxel in Subjects With Recurrent Previously Treated Locally Advanced or Metastatic NSCLC

NCT02346370 · clinicaltrials.gov ↗

PHASE1

Phase

TERMINATED

Status

16

Enrollment

INDUSTRY

Sponsor class

Stopped Changing standard of care therapy regimen

Conditions

Non-small Cell Lung Cancer

Interventions

DRUG: PEGylated recombinant human hyaluronidase PH20
DRUG: Docetaxel

Sponsor

Halozyme Therapeutics